MDACC Study No:ID02-040 ( NCT No: NCT00068575)
Title:A Phase II Trial of Pancreaticoduodenectomy Plus Postoperative Cisplatin, Interferon Alfa-2b, and 5-FU Combined with Radiation Treatment for Patients with Resected Pancreatic Adenocarcinoma
Principal Investigator:Peter W. Pisters
Treatment Agent:Interferon Alpha-2B; Radiation
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if the combination of
5-fluorouracil (5-FU), cisplatin, and interferon alfa-2b (Intron-A), given with
radiation treatment, can help to prevent the growth of cancers in the
pancreas. The safety of this combination treatment will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Pancreas
Phase of Study:Phase II
Treatment Agents:Interferon Alpha-2B
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:No expected/planned hospitalization.
Supported By:N/A
Return Visit:After treatment - 2-4 months for the first 2 years, every 3-5 months for the
third year, and every 5-7 months for the 4th and 5th years.
Home Care:None

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Peter W. Pisters
Dept:Surgical Oncology
For Clinical Trial Enrollment:713-794-1572
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults